Recurrent erysipelas: Predisposing factors and costs of prophylaxis

  title={Recurrent erysipelas: Predisposing factors and costs of prophylaxis},
  author={Christina Jorup-R{\"o}nstr{\"o}m and S. Britton},
SummaryAfter an average follow-up time of three years, recurrent erysipelas was observed in 29% of 143 patients admitted primarily with erysipelas. Nineteen patients (13%) had two or more recurrences during this period. The predisposing factor with the highest recurrence rate was venous insufficiency. Regular prophylaxis with phenoxymethylpenicillin (or erythromycin in penicillin allergics) after the second recurrence may be cost-effective. This antibiotic prophylaxis is only recommended in… 
Antibiotic prophylaxis in recurrent erysipelas
Patients with venous insufficiency or lymphatic congestion who had suffered two or more episodes of erysipelas during the previous 3 years and were admitted to the Infectious Disease Department at Roslagstull Hospital, Stockholm, Sweden, between November 1988 and November 1991 were included.
Recurrent erysipelas despite antibiotic prophylaxis: an analysis from case studies.
Investigation of recurrences of erysipelas during prophylactic antibiotic treatment indicated noncompliance, incorrect selection and insufficient dosing of antibiotics, and causative pathogens other than streptococci as demonstrable causes of the recurrence of erysipelas.
Recurrent Erysipelas: 47 Cases
The results showed that erysipelas recurrence has the same risk factors as single episodes and underlines the potential benefit of oral or parenteral antibiotic prophylaxis to prevent recurrences.
Recurrent erysipelas - risk factors and clinical presentation
Overall, lymphedema was the most prominent risk factor for recurrence although the distribution of predisposing conditions varies depending on the site of erysipelas.
Recurrent Cellulitis: Risk Factors, Etiology, Pathogenesis and Treatment
The medical literature provides convincing evidence that antimicrobial prophylaxis can markedly reduce the frequency of relapse of erysipelas and treatment options in patients with penicillin allergy are limited by the rising prevalence of macrolide resistance among group A streptococci.
Benzathine penicillin G once-every-3-week prophylaxis for recurrent erysipelas a retrospective study of 132 patients
Benzathine penicillin G 1.2 MU once every 3 weeks is an effective and well-tolerated prophylaxis of recurrent erysipelas with good patient adherence to the treatment and further studies to determine the appropriate duration are necessary.
Comorbidities as Risk Factors for Acute and Recurrent Erysipelas
Investigation and treatment of modifiable risk factors are expected to reduce the risk of a subsequent episode of erysipelas on the lower limbs and identify the comorbidities associated with it.
Clinical Presentation and Laboratory Characteristics in Acute and Recurrent Erysipelas
Erysipelas is more frequent in older people; it has seasonal character and tendency to reoccur, and identifying clinical and laboratories characteristics of those at risk may prevent recurrence and long term comorbidities.
Intracellular Streptococcal Uptake and Persistence: A Potential Cause of Erysipelas Recurrence
It is concluded that the current antibiotic treatment strategies and elimination of conventional risk factors employed in erysipelas management are insufficient to prevent erYSipelas recurrence and demands for novel antibiotic strategies capable of eradicating intracellular streptococcal persistence.


The course, costs and complications of oral versus intravenous penicillin therapy of erysipelas
It is suggested that erysipelas without complications should be treated orally, as the difference in administration time and drug cost was considerable.
[Therapy and prophylaxis of recurrent erysipelas (author's transl)].
Frequency of recidivation significantly decreased in 3 patients; no improvement was achieved in the three last patients.
Postmastectomy Edema and Recurrent Cellulitis: Prevention and Treatment
Edema of the arm with associated recurrent bouts of cellulitis, occurring immediately or as late as twenty years after treatment of breast cancer, has been a very common and major complication since
Streptococcal infections, In: Harrison's principles of medicine, (10th ed
  • 1983
Rezidivierendes Erysi
  • 1981
Group A p-hemolytic streptococcemia
  • Mayo Clin. Proc
  • 1973
Zur Therapie und Prophylaxe des rezidivieren - den Erysipels
  • Med . Klin .
  • 1976